Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-04-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2023年度独立董事述职报告（苏为科）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 by an independent director of the company. It details the director's background, independence, attendance at meetings, exercise of duties, communication with auditors, and evaluation of company matters during the year. It is a formal report on the director's activities and responsibilities over the year, not a general annual report or financial statement. It does not contain financial statements or audit opinions but focuses on governance and director duties. This fits the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document is about the independent director's annual work report, which is a management/board-related disclosure rather than a full annual report or audit report.
2024-04-28 Chinese
奥锐特药业股份有限公司关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (553 characters) from a company about its wholly-owned subsidiary receiving a High-Tech Enterprise Certificate. It includes details about the certificate, its validity, and the impact on the company's tax rate and operations. There is no financial data, no mention of a report being attached or published, and no regulatory form references. The content is an official company announcement about a specific event affecting the company but not related to financial results, management changes, or shareholder votes. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-02-20 Chinese
奥锐特药业股份有限公司关于回复上海证券交易所《关于奥锐特药业股份有限公司向不特定对象发行可转债的上市审核委员会会议意见落实函》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 奥锐特药业股份有限公司 regarding the company's response to the Shanghai Stock Exchange's comments on its application to issue convertible bonds to unspecified investors. It mentions the submission of related documents and the pending approval from the China Securities Regulatory Commission. The document is short (659 characters) and serves as a regulatory update about the financing process rather than a detailed financial report or the issuance of the bonds themselves. It does not contain financial statements or detailed analysis but is an official disclosure related to capital raising activities. Therefore, it fits best under Capital/Financing Update (CAP).
2024-02-06 Chinese
关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券上市审核委员会会议意见落实函回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed response report from a pharmaceutical company (奥锐特药业股份有限公司) and its sponsor (海通证券股份有限公司) addressing the Shanghai Stock Exchange's review committee's opinions regarding the company's issuance of convertible bonds to unspecified investors. The content includes extensive discussion on the feasibility, market analysis, production capacity, sales data, and risk assessment related to the new production capacity funded by the bond issuance. It also contains formal statements and confirmations by the company's chairman and the sponsor's legal representatives. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory response document related to a capital raising activity (issuance of convertible bonds) and the associated review process. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8252 characters) and detailed content support this classification with high confidence.
2024-02-06 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券募集说明书（上会稿）（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for the issuance of convertible bonds to unspecified investors. It contains detailed information about the bond issuance, including credit ratings, risk factors, dividend policies, management commitments, and extensive financial and operational disclosures. The document is lengthy (15,000 characters) and includes detailed financial and management analysis related to the bond issuance. This type of document is a capital raising disclosure related to financing activities rather than a general annual report, earnings release, or other categories. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-02-06 Chinese
奥锐特药业股份有限公司关于向不特定对象发行可转换公司债券获得上海证券交易所上市审核委员会审议通过的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval by the Shanghai Stock Exchange Listing Review Committee for the company's application to issue convertible bonds to unspecified investors. It mentions the need for further approval by the China Securities Regulatory Commission before implementation. The content is about a financing activity and capital raising process, not a full financial report or earnings release. The document length is short (532 characters), and it is clearly an update on capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-01-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.